A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer

  • STATUS
    Recruiting
  • End date
    Jun 30, 2024
  • participants needed
    40
  • sponsor
    Shanghai Zhongshan Hospital
Updated on 22 January 2021

Summary

  1. Target population: patients with advanced biliary tract cancer (including gallbladder carcinoma, intrahepatic and extrahepatic cholangiocarcinoma) .
  2. Primary objective: progression free survival (PFS)/ overall survival (OS) of first-line chemotherapy plus PD-1 antibody (Toripalimab) in patients with advanced biliary tract cancer.

Secondary objectives:

  1. objective response rate (ORR) of first-line chemotherapy plus PD-1 antibody (Toripalimab)
  2. safety of first-line chemotherapy plus PD-1 antibody (Toripalimab)

3.Trial design: This is a monocenter, single arm, phase II study to evaluate the efficacy and safety of first-line chemotherapy plus PD-1 antibody (Toripalimab) in patients with advanced advanced biliary tract cancer.

4.Treatment plan: Patients will be given treatment as below once recruited: PD-1 antibody Toripalimab240mg, iv, q3wcombined with GS regimen(gemcitabine 1000mgm2 d1,d8 + S1 40-60mg bid*14dQ21d).

The treatment will be continued until emerging of disease progression or intolerable adverse effects (The upper time limit for treatment is 2 years).

5.Number of subjects: 40 patients. Number of centers: 1 sites ( Fudan University Affiliated Zhongshan Hospital).

Description

Backgrounds

Toripalimab (JS-001) is a PD-1 antibody developed by Shanghai Jun Shi Biomedical technology Co. Ltd. Nowadays, eighteen clinical trials of this drug have been conducted in patients with different types of advanced malignant tumor. Until now, Toripalimab has exhibited favorable safety in recruited patients. Incidence rate of SAE is 14.7%. JS001-Ib-CRP-1.0 is a phase Ib/II basket trial, aiming at evaluating safety and efficacy of JS001 in treating advanced gastric adenocarcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma and head and neck squamous cell carcinoma.The interim analyses results of 161 patients show that the ORR is 22.4%.

Now, the standard chemotherapies regimen for advanced biliary tract cancer include gemcitabine, platinum and fluorouracil; Considering the synergistic effect of chemotherapy and immune therapy, we choose GS regimen (gemcitabine+S1) to combine Toripalimab.

We will shut down the study in advance, if unpredicted SAE or low efficacy occur.

Patients with abnormal autoimmune status, unfavorable body function, factors impeding drug taking, absorption and metabolism will be excluded. Study participants with disease progression or severe/ intolerant toxicity during treatment will withdraw the study.

Hyper-progressive disease is defined as 1) progression 2) more than doubled growth rate 3) tumor volume increase >50% in 2 months after initialing the treatment.

Details
Condition Biliary neoplasm, Biliary Tract Cancer, Urothelial Tract Cancer, Urothelial Tract Cancer, Biliary Tract Cancer, biliary cancer
Treatment GS+Toripalimab
Clinical Study IdentifierNCT03796429
SponsorShanghai Zhongshan Hospital
Last Modified on22 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female. Age 18 years and 75 years
histologically documented advanced biliary duct cancer, including gallbladder cancer, intrahepatic and extrahepatic cholangiocarcinoma, specimen within a year available for test (at least 10 pathological sections)
at least one measurable lesion in abdominal CT/MRI according to RESIST 1.1 is required
Karnofsky score 80
Adequate hematological function: Neutrophil count 1.5 109/L, Platelets 100 109/L and Hemoglobin 90g/L
Adequate liver function: Total bilirubin 1.5 upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) < 2.5 ULN in the absence of liver metastases, or < 5 ULN in case of liver metastases. ALP 2.5 upper limit of normal (ULN); ALB 30g/L
Adequate renal function: Serum creatinine 1.5 x ULN, and creatinine clearance 60 ml/min
Adequate coagulation function: INR/PT 1.5 x ULN, aPTT 1.5 x ULN
No serious concomitant disease that will threaten the survival of patients to less than 5 years
Written (signed) informed consent
Good compliance with the study procedures, including lab and auxiliary examination and treatment
Female patients should not be pregnant or breast feeding
Agree to take contraception measures during treatment and in 120 days after last dose of Toripalimab or in 180 days after last dose of chemo

Exclusion Criteria

history of chemo, radiation, immune therapy or radical resection for the biliary tract cancer, except those patients who relapsed after 6 months since the last time of adjuvant therapy
patients with active autoimmune disease or history of refractory autoimmune disease
patients with active malignant tumor in recent 2 years, except the tumor studied in this research or cured locally tumor like resected basal cell or squamous cell skin cancer, superficial bladder cancer, cervical or breast carcinoma in situ
uncontrollable pleural effusion, pericardial effusion, or ascites in 2 weeks before recruitment
patients who have digestive tract bleeding in 2 weeks before recruitment or with high risk of bleeding
perforation / fistula of GI tract in 6 months before recruitment
losing over 20% body weight in 2 months before recruitment
pulmonary disease history: interstitial pulmonary disease, non-infective pneumonitis, pulmonary fibrosis, acute pulmonary disease
uncontrollable systemic diseases, including diabetes, hypertension, etc
severe chronic or active infections in need of systemic antibacterial, antifungal, or antiviral treatment, including TB or HIV, etc
patients with untreated chronic hepatitis B or HBV DNA over 500 IU/ml or positive HCV RNA
patients with any cardiovascular risk factors below
cardiac chest pain occurring in 28 days before recruitment, defined as moderate pain that limits daily activity
pulmonary embolism with symptoms occurring in 28 days before recruitment
acute myocardial infarction occurring in 6 months before recruitment
any history of heart failure reaching grade 3/4 of NYHA in 6 months before recruitment
ventricular arrhythmias of Grade 2 or grater in 6 months before recruitment, or accompanied by supraventricular tachyarrhythmias requiring medical treatment
cerebrovascular accident within 6 months before recruitment
patients with peripheral neuropathy NCI CTC AE grade 1, except those with only deep tendon reflex disappearing
moderate or severe renal injury [creatinine clearance rate50 ml/min (according to Cockroft & Gault equation)], or Scr>ULN
allergic to any drug in this study
history of allogeneic stem cell transplantation or organ transplantation
use of steroids (dosage>10mg/d prednisone) or other systemic immune suppressive therapy in 14 days before recruitment, except patients treated with regimens below: a. steroids for hormone replacement (dosage>10mg/d prednisone); b. steroids for local application with little systemic absorption; c. short -term ( 7 days) steroids for preventing allergy or vomiting
vaccinated with live vaccine in 4 weeks before recruitment
receiving immune (interleukin, interferon, thymin) treatment or treatment of other trials in 28 days before recruitment
receiving palliative radiation in 14 days before recruitment
history of anti PD-1, PD-L1, PD-L2 or any other specific T cell co-stimulation or checkpoint pathway targeted treatment
receiving operation in 28 days before recruitment, only if the operation is a minimally invasive one e.g. PICC
for patients with uncontrolled epilepsy, CNS diseases or history of mental disorder, researchers should evaluate whether their diseases will impede their signing of informed consent or compliance of treatment
existing of potential situation which will impede drug administration or affect toxicity analysis or alcohol/ drug abuse
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note